Our News Bureau – Mumbai
Ind-Swift Laboratories received US FDA approval for its five Active Pharmaceutical Ingredients (APIs) manufactured at its Derabassi manufacturing facility. With this approval, the company has entered in the league of big pharma majors having multi product approval for its facilities. The facilities of the company were inspected in mid 2011.
As per issued company’s press release, the Derabassi manufacturing facility of Ind-Swift Laboratories which is one of the largest API manufacturing facilities in northern India. The products for which company has got the approval are: naratriptan hydrochloride (anti-migraine); ropinirole hydrochloride (anti-Parkinson’s disease); donepezil hydrochloride(anti-Alzheimer’s disease); acamprosate calcium (Anti-alcohol dependence), and clarithromycin (Macrolide Antibiotic). The worldwide market for these products is $5 billion. With this approval the company will be able to sell its products to US market.
Commenting on the development NR Munjal Vice-Chairman and Managing Director stated, “This multi product approval will give multi-fold aggression to the sales as we have good presence in the US through our US subsidiary and we expect this approval to give additional 50-60 per cent growth in the US sales.” He further added that the company is already supplying three products commercially to the US market which presently is contributing three per cent of the sales and the company expects this figure to reach to seven to eight per cent in the next two to three years.